EGFR and neoplasm: Similarly to the molecular findings observed in patients progressing on gefitinib and erlotinib, results from tumor re-biopsy and NGS analysis performed on tissue DNA and circulating tumor DNA in patients progressing on osimertinib identified secondary mutations interfering with drug binding, the most frequent being EGFR C797S [41,42,43,46].